IOVA Investors Have the Opportunity to Lead the Iovance Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Iovance Biotherapeutics, Inc. due to significant declines in revenue and misleading statements made by the company regarding its business operations and prospects [2][4]. Financial Performance - Iovance reported a quarterly total product revenue of $49.3 million for Q1 2025, down from$73.7 million in the previous quarter, indicating a substantial decline [5]. - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million -$475 million to $250 million -$300 million, representing a reduction of over 40% at the midpoint [5]. Legal Proceedings - A federal securities class action has been filed against Iovance, with a deadline of July 14, 2025, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that Iovance made materially false and misleading statements and failed to disclose adverse facts about its business, including issues with new Authorized Treatment Centers (ATCs) and patient treatment timelines [4]. Market Reaction - Following the release of the disappointing financial results, Iovance's share price fell by $1.42, or 44.8$1.75 per share on May 9, 2025, with unusually high trading volume [6].